Effects of oxandrolone on plasma lipoproteins in patients with type IIa, IIb and IV hyperlipoproteinemia: occurrence of hypo-high density lipoproteinemia.
The effects of oxandrolone on plasma lipids and lipoprotein composition in patients with type IIa, IIb and IV hyperlipoproteinemia were investigated. Oxandrolone (4 mg/day, for 28 days) induced a significant reduction in plasma and VLDL triglyceride. Reciprocal elevation of LDL cholesterol was observed in 8 of 10 type IV patients and in 2 of 5 type IIb patients. In patients with type IV hyperlipoproteinemia, significant reduction of plasma apolipoproteinB and VLDL apolipoprotein B and inverse LDL apolipoprotein B increment was observed after treatment with oxandrolone. HDL cholesterol was decreased. Hypo-high density lipoproteinemia defined as HDL cholesterol concentration below 40 mg/100 ml occurred in 7 of 10 type IV, 3 of 6 type IIb and 1 of 4 type IIa patients.
D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000097:blood; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood* / Q000188:drug therapy; D006953:Hyperlipoproteinemia Type IV / Q000097:blood* / Q000188:drug therapy; D008074:Lipoproteins / Q000097:blood; D008075:Lipoproteins, HDL / Q000097:blood*; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D010074:Oxandrolone / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D014280:Triglycerides; D010074:Oxandrolone; D002784:Cholesterol